 |
 |
Birmingham, Sandwell, Solihull and environs APC Formulary
Maintained by Midlands and Lancashire Commissioning Support Unit |
Formulary Chapter 8: Malignant disease and immunosuppression - Full Section
|
Notes:
For the most up to date list of agents funded by the Cancer Drugs Fund, please see Cancer Drug Fund list |
Numbers in brackets indicate counts of (Formulary items, Non Formulary items)
|
08.01 |
Cytotoxic drugs
(0,1)
|
|

Side-effects of cytotoxic drugs
(0,1)
|
|

Drugs for cytotoxic-induced side-effects
(3,4)
|
08.01.01 |
Alkylating drugs
(9,0)
|
08.01.02 |
Anthracyclines and other cytotoxic antibiotics
(2,0)
|
08.01.03 |
Antimetabolites
(11,0)
|
08.01.04 |
Vinca alkaloids and etoposide
(1,2)
|
08.01.05 |
Other antineoplastic drugs
(37,1)
|
|

Amsacrine
(0,1)
|
|

Arsenic trioxide
(1,0)
|
|

Bevacizumab
(1,0)
|
|

Bexarotene
(1,0)
|
|

Bortezomib
(1,0)
|
|

Brentuximab vedotin
(1,0)
|
|

Cetuximab
(1,0)
|
|

Crisantaspase
(1,0)
|
|

Dacarbazine and Temozolomide
(2,0)
|
|

Erlotinib
(1,0)
|
|

Hydroxycarbamide
(1,0)
|
|

Ipilimumab
(1,0)
|
|

Mitotane
(1,0)
|
|

Panitumumab
(1,0)
|
|

Pentostatin
(0,1)
|
|

Platinum compounds
(1,2)
|
|

Porfimer sodium and temoporfin
(0,2)
|
|

Procarbazine
(1,0)
|
|

Protein kinase inhibitors
(22,1)
|
|

Taxanes
(4,0)
|
|

Topoisomerase I inhibitors
(1,1)
|
|

Trabectedin
(0,1)
|
|

Trastuzumab
(3,0)
|
|

Tretinoin
(0,1)
|
|

Vismodegib
(0,1)
|
08.02 |
Drugs affecting the immune response
(0,2)
|
|

Immunosuppressant therapy (0,0)
|
08.02.01 |
Antiproliferative immunosuppressants
(3,0)
|
08.02.02 |
Corticosteroids and other immunosuppressants
(5,2)
|
08.02.03 |
Anti-lymphocyte monoclonal antibodies
(12,0)
|
08.02.04 |
Other immunomodulating drugs
(5,3)
|
|

Interferon Alfa
(2,0)
|
|

Interferon beta
(6,0)
|
|

Interferon gamma (0,0)
|
|

Aldesleukin
(0,1)
|
|

BCG bladder instillation (0,0)
|
|

Canakinumab (0,0)
|
|

Dimethyl fumarate
(1,0)
|
|

Fingolimod
(1,0)
|
|

Glatiramer acetate
(1,0)
|
|

Histamine (0,0)
|
|

Lenalidomide, pomalidomide, and thalidomide
(2,0)
|
|

Mifamurtide
(1,0)
|
|

Natalizumab
(1,0)
|
|

Teriflunomide
(1,0)
|
08.03 |
Sex hormones and hormone antagonists in malignant disease (0,0)
|
08.03.01 |
Oestrogens
(1,1)
|
08.03.02 |
Progestogens
(3,0)
|
08.03.03 |
Androgens (0,0)
|
08.03.04 |
Hormone antagonists (0,0)
|
08.03.04.01 |
Breast cancer
(5,1)
|
08.03.04.02 |
Prostate cancer and gonadorelin analogues
(1,0)
|
|

Gonadorelin analogues
(1,1)
|
|

Anti-androgens
(11,1)
|
|

Gonadotrophin-releasing hormone antagonists (0,0)
|
08.03.04.03 |
Somatostatin analogues
(5,0)
|
|
|
|